Cargando…

Clinical Experience with Insulin Detemir in Patients with Type 2 Diabetes from the Near East Countries

INTRODUCTION: This study aimed at determining the clinical safety and efficacy of insulin detemir (IDet) in combination with oral anti-diabetic drugs (OADs) in type 2 diabetes (T2D) patients from four Near East Countries (Israel, Jordan, Pakistan and Lebanon). METHODS: This prospective observational...

Descripción completa

Detalles Bibliográficos
Autores principales:	Echtay, Akram, Tsur, Anat, Hasan, Mohammad I., Abu-Hijleh, M. Omar, Al Khatib, Nidal, Andari, Emile, Atallah, Paola, Qureshi, Saleem, Zafar, Jamal, Sandalci, Levent, Ademogulları, Asude, Haddad, Jihad, Dagan, Bracha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889319/ https://www.ncbi.nlm.nih.gov/pubmed/24108581 http://dx.doi.org/10.1007/s13300-013-0041-z

Ejemplares similares

Experts’ opinion on the detection and management of prediabetes in Lebanon
por: Andari, Emile, et al.
Publicado: (2021)

Insulin Detemir Causes Lesser Weight Gain in Comparison to Insulin Glargine: Role on Hypothalamic NPY and Galanin
por: Zafar, Mohammad Ishraq, et al.
Publicado: (2014)

Insulin Detemir in the Treatment of Type 1 and Type 2 Diabetes
por: Philips, Jean-Christophe, et al.
Publicado: (2006)

Cerebrocortical Beta Activity in Overweight Humans Responds to Insulin Detemir
por: Tschritter, Otto, et al.
Publicado: (2007)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander, Priscilla A
Publicado: (2012)

Insulin Detemir in Pregnancy: A Small but Significant Step Forward?
por: McElduff, Aidan
Publicado: (2012)

The role of insulin detemir in overweight type 2 diabetes management
por: Demssie, Yared N, et al.
Publicado: (2009)

Type 2 Diabetes Mellitus Management and Body Mass Index: Experiences with Initiating Insulin Detemir in the A(1)chieve Study
por: Khamseh, Mohammed E., et al.
Publicado: (2014)

Detemir as a once-daily basal insulin in type 2 diabetes
por: Nelson, Scott E
Publicado: (2011)

Sustained Treatment with Insulin Detemir in Mice Alters Brain Activity and Locomotion
por: Sartorius, Tina, et al.
Publicado: (2016)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Eastern Saudi Arabia cohort of the A(1)chieve study
por: Hashim, Faisal, et al.
Publicado: (2013)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
por: Poon, Kitty, et al.
Publicado: (2010)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2–16 Years
por: Thalange, Nandu, et al.
Publicado: (2016)

Prevalence and risk factors of vascular complications in type 2 diabetes mellitus: Results from discover Middle East and Africa cohort
por: Hafidh, Khadija, et al.
Publicado: (2022)

Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes
por: Philis-Tsimikas, Athena
Publicado: (2008)

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
por: Peterson, Gregory E
Publicado: (2009)

Safety and Effectiveness of Insulin Detemir in Different Age-Groups in the A(1)chieve Study
por: Malek, Rachid, et al.
Publicado: (2013)

Insulin detemir may be less efficacious in patients with nonalcoholic fatty liver disease and hypertriglyceridemia
por: Whyte, Martin, et al.
Publicado: (2015)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

Reduced Efficacy of Insulin Detemir in Controlling Hyperglycemia during Pregnancy: An Interesting Case Report
por: Pande, Arun, et al.
Publicado: (2018)

Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 Diabetes: Assessment of Detemir Administration in a Progressive Treat-To-Target Trial (ADAPT)
por: Le Floch, Jean-Pierre, et al.
Publicado: (2009)

554. Does Protease Inhibitor (PI) Monotherapy Select Primary PI Resistance?
por: Saling, Christopher, et al.
Publicado: (2018)

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics
por: Le Floch, Jean-Pierre
Publicado: (2010)

Mixing Insulin Aspart With Detemir Does Not Affect Glucose Excursion in Children With Type 1 Diabetes
por: Nguyen, Thanh M., et al.
Publicado: (2010)

All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine
por: Strandberg, Arto Y., et al.
Publicado: (2016)

Adiponectin, Leptin, and Leptin Receptor in Obese Patients with Type 2 Diabetes Treated with Insulin Detemir
por: Olczyk, Paweł, et al.
Publicado: (2017)

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus
por: Porcellati, Francesca, et al.
Publicado: (2011)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Detemir plus aspart and glulisine induced lipoatrophy: 2015 literature review and report of a new case
por: Saberi, Sima, et al.
Publicado: (2015)

Insulin Allergy to Detemir Followed by Rapid Onset of Diabetic Ketoacidosis: A Case Report and Literature Review
por: Teo, Chong Boon, et al.
Publicado: (2022)

Cycle-skipping strategy with intake air cut off for natural gas fueled Si engine
por: Tunçer, Erdal, et al.
Publicado: (2021)

Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations
por: Sonmez, Alper, et al.
Publicado: (2022)

Idiopathic Hypoparathyroidism and Severe Hypocalcemia in Pregnancy
por: Richa, Carine Ghassan, et al.
Publicado: (2018)

Insulin Detemir Reduces Weight Gain as a Result of Reduced Food Intake in Patients With Type 1 Diabetes
por: Zachariah, Sunil, et al.
Publicado: (2011)

Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
por: Young, Jason R., et al.
Publicado: (2010)

Weight‐sparing effect of insulin detemir: a consequence of central nervous system‐mediated reduced energy intake?
por: Russell‐Jones, D., et al.
Publicado: (2015)

Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes
por: Asias, Bernadette D., et al.
Publicado: (2015)

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK
por: Thalange, Nandu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7p7fslp2vshvejmoq5re7g8d60